Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03638258
Other study ID # ARQ-151-201
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 21, 2018
Est. completion date May 29, 2019

Study information

Verified date August 2022
Source Arcutis Biotherapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a parallel group, double blind, vehicle-controlled study in which roflumilast (ARQ-151) cream 0.3%, roflumilast cream 0.15%, or vehicle cream is applied once daily (QD) for 84 days to subjects with chronic plaque psoriasis involving between 2 and 20% body surface area.


Recruitment information / eligibility

Status Completed
Enrollment 331
Est. completion date May 29, 2019
Est. primary completion date May 29, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants legally competent to sign and give informed consent - Males and females ages 18 years and older (inclusive) - Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator - Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial. - In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis. - Subjects are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator. Exclusion Criteria: - Planned excessive exposure of treated area(s) to either natural or artificial sunlight or tanning bed. - Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding. - Previous treatment with roflumilast cream or its active ingredient - Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator. - Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication. - Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Roflumilast Cream 0.3%
Applied once daily for 12 weeks
Roflumilast Cream 0.15%
Applied once daily for 12 weeks
Vehicle Cream
Applied once daily for 12 weeks

Locations

Country Name City State
Canada Arcutis Clinical Site 10 Ajax Ontario
Canada Arcutis Clinical Site 25 London Ontario
Canada Arcutis Clinical Site 26 Markham Ontario
Canada Arcutis Clinical Site 32 Oakville Ontario
Canada Arcutis Clinical Site 17 Peterborough Ontario
Canada Arcutis Clinical Site 11 Surrey British Columbia
Canada Arcutis Clinical Site 18 Surrey British Columbia
Canada Arcutis Clinical Site 30 Waterloo Ontario
Canada Arcutis Clinical Site 36 Windsor Ontario
Canada Arcutis Clinical Site 38 Winnipeg Manitoba
United States Arcutis Clinical Site 35 Beverly Hills California
United States Arcutis Clinical Site 39 Bexley Ohio
United States Arcutis Clinical Site 34 Clinton Township Michigan
United States Arcutis Clinical Site 19 College Station Texas
United States Arcutis Clinical Site 33 Detroit Michigan
United States Arcutis Clinical Site 20 Fridley Minnesota
United States Arcutis Clinical Site 14 High Point North Carolina
United States Arcutis Clinical Site 13 Houston Texas
United States Arcutis Clinical Site 37 Houston Texas
United States Arcutis Clinical Site 21 Louisville Kentucky
United States Arcutis Clinical Site 12 Miami Florida
United States Arcutis Clinical Site 22 New York New York
United States Arcutis Clinical Site 31 Norfolk Virginia
United States Arcutis Clinical Site 29 Northridge California
United States Arcutis Clinical Site 15 Pittsburgh Pennsylvania
United States Arcutis Clinical Site 23 San Antonio Texas
United States Arcutis Clinical Site 28 San Diego California
United States Arcutis Clinical Site 16 Sanford Florida
United States Arcutis Clinical Site 27 Santa Monica California
United States Arcutis Clinical Site 24 Webster Texas

Sponsors (1)

Lead Sponsor Collaborator
Arcutis Biotherapeutics, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6 The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 6 is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity. Week 6
Secondary Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity. Weeks 4, 8, and 12
Secondary Change From Baseline in Modified Psoriasis Area Severity Index (mPASI) Score The percent change from baseline in mPASI score is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. For scoring, the body is divided into four sections (head [h]: 10% of a person's skin; arms [a] 20%; trunk [t] 30%; legs (l] 40%); for each section, the percent of area involved is estimated from 0 (0% involved) to 6 (90 to 100% involved). Then, within each area, the severity is estimated by three clinical signs: erythema ('E'; redness), induration ('T'; thickness), and desquamation ('S'; scaling). Severity parameters are measured on a scale of 0 to 4, from none to maximum severity possible. Each of these areas is scored by itself, and then the four scores are combined into the final mPASI, using the formula mPASI = 0.1 (Eh + Th + Sh) Ah + 0.2 (Ea + Ta + Sa) Aa + 0.3 (Et + Tt + St) At + 0.4 (El + Tl + Sl) Al. Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary Percent Change From Baseline in Body Surface Area (BSA) Affected The BSA affected by psoriasis was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. The mean percent change from baseline in BSA is presented. Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' Plus a 2-Grade Improvement From Baseline The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') plus a 2-grade improvement from baseline is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity. Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary Percentage of Participants With an Intertriginous Area Investigator Global Assessment (I-IGA) Score of 'Clear' or 'Almost Clear' Who Had at Least Mild Lesions at Baseline The percentage of participants (who had intertriginous area involvement with an I-IGA score of at least mild at baseline) with at least a 2-grade improvement in I-IGA score at Weeks 4, 6, 8, and 12 is presented. Weeks 4, 6, 8, and 12
Secondary Change From Baseline in Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. The mean (SD) change in WI-NRS score from baseline is presented. Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary Percentage of Participants With Baseline Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score =6 Who Experienced a 4-point Reduction The percentage of participants who had baseline WI-NRS scores =6 who achieved a 4-point reduction in WI-NRS score at Weeks 4, 6, 8, and 12 is reported. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-75 (mPASI-75) Compared to Baseline The percentage of subjects achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-90 (mPASI-90) Compared to Baseline The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. The percentage of subjects achieving a 90% reduction in mPASI (eg, mPASI-90) score relative to baseline is presented. Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary Change From Baseline in Psoriasis Symptom Diary (PSD) Total Score The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 11 ("worst imaginable symptoms"). Scores range from 0 to 176, with higher scores indicating greater symptom severity. The mean (SD) change in PSD total score relative to baseline is presented for each treatment arm. Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary Change From Baseline in Itch-Related Sleep Loss Numeric Rating Scale (NRS) Score The Itch-Related Sleep Loss NRS is a single item scale scored from 0 ("no itch-related sleep loss") to 10 ("itch-related sleep loss as bad as it could be") assessing the severity of itch-related sleep loss in the past 24 hours. The mean (SD) change from the baseline NRS score is presented for each treatment arm. Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary Change From Baseline in Dermatology Life Quality Index (DLQI) Score The DLQI is a 10-item scale asking subject to rate the severity of symptoms during the past week. Each item is scored from 0 ("not at all" or "not relevant") to 3 or 4 ("very much") [2 questions are scored 0 to 3 and 8 questions are scored 0 to 4]. The total DLQI score ranges from 0 to 48, with higher scores indicating greater symptom severity. The mean (SD) change from baseline DLQI score is presented. Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary Responses to Individual Questions of the Psoriasis Symptom Diary (PSD) Two items from the PSD asking participants to rate the overall severity of psoriasis-related itching and pain during the past 24 hours are presented. Each item is scored on an 11-point scale ranging from 0 ("no symptom") to 10 ("worst imaginable symptom"), with lower scores indicating lower symptoms severity. The mean (SD) score is presented for each treatment arm. Weeks 4, 6, 8, and 12
See also
  Status Clinical Trial Phase
Completed NCT01194219 - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Phase 3
Recruiting NCT06030076 - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed NCT04263610 - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Phase 4
Completed NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Phase 2
Completed NCT05600036 - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Not yet recruiting NCT05036889 - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. N/A
Completed NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT02881346 - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting NCT02611349 - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis Phase 3
Completed NCT02251678 - Evaluate the Effect of Elimune Capsules Phase 1
Completed NCT01987843 - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2
Terminated NCT01708629 - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Phase 3
Completed NCT01230138 - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis Phase 2
Withdrawn NCT00747032 - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis Phase 3
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Suspended NCT01228656 - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate Phase 2
Completed NCT00540618 - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis Phase 2
Completed NCT05442788 - A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis Phase 1